# Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)

> **NCT00651482** · PHASE2 · TERMINATED · sponsor: **Sandy Srinivas** · enrollment: 10 (actual)

## Conditions studied

- Kidney Neoplasms
- Kidney (Renal Cell) Cancer

## Interventions

- **DRUG:** Everolimus
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT00651482
- **Lead sponsor:** Sandy Srinivas
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** slow accrual
- **Last updated:** 2017-04-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00651482

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00651482, "Treatment of Refractory Metastatic Renal Cell Carcinoma With Bevacizumab and RAD001 (Everolimus)". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00651482. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*